Dabrafenib + Trametinib in Patients w/rare BRAF V600E Mutated Solid Tumor (CDRB436IIC01) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.

¿Cuál es la Condición que se está estudiando?

Unresectable or Metastatic BRAF V600E Mutation Positive Solid Tumors

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with unresectable or metastatic BRAF V600E mutation positive solid tumors
Have not received dabrafenib-trametinib previously for your disease or have not received it for more than one year for any other malignancy

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, we will collect information related to your cancer and treatment and enter it into a database that we will keep indefinitely. This information will help us better understand how the drug combination works for people who have this rare mutation.

Detalles del Estudio

Título Completo

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Investigador Principal